Clinical Trial Update: DEX vs SEVO in Congenital Heart Surgery [Phase 4]

View source ↗

Summary

Phase 4 trial updating dexmedetomidine (DEX) versus sevoflurane (SEVO) in congenital heart surgery is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Defects Congenital

Drugs mentioned

• Dex
• SEVO (sevoflurane)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Heart Defects, Congenital | Phase 4 | Status: NOT_YET_RECRUITING